Are there gender differences in anti-HIV drug efficacy?

©2012 Mary Ann Liebert, Inc., publishers

Women comprise nearly half of the HIV-infected population worldwide, but these 15.5 million women tend to be under-represented in clinical trials of anti-HIV drug therapies. The U.S. Food and Drug Administration (FDA) has created a database from 40 clinical studies to assess gender differences in the efficacy of antiretroviral treatments. The results of this study are presented in an article in AIDS Patient Care and STDs.

Guoxing Soon and coauthors from the FDA and University of Texas Southwestern Medical Center, Dallas, TX, found that women represented only about 20% of the subjects in randomized clinical trials submitted to the FDA between 2000 and 2008. The article "Meta-Analysis of Gender Differences in Efficacy Outcomes for HIV-Positive Subjects in Randomized Controlled Clinical Trials of Antiretroviral Therapy (2000-2008)" compares the effectiveness of anti- regimens reported for women versus men overall and among various subgroups.

The authors found no statistically or clinical significant differences between women and men in outcomes with regard to viral load after 48 weeks. However, they did report significant favoring males based on subgroup analyses.

"This is a critical area of research in terms of developing new HIV therapies," says Editor-in-Chief Jeffrey Laurence, MD, Director of the Laboratory for Research at Weill Medical College of Cornell University, New York, NY. "Mounting evidence indicates that metabolism of certain drugs varies in men vs. women, and side effects that interfere with adherence to these medications may also be manifest differently."

More information: http://www.liebertpub.com/apc

add to favorites email to friend print save as pdf

Related Stories

US approves new HIV drug

May 21, 2011

The US Food and Drug Administration on Friday approved a new drug, Edurant, to fight HIV in combination with other antiretrovirals already on the market.

HIV drug maraviroc effective for drug-resistant patients

Oct 01, 2008

As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. Now, maraviroc, the first of a new class of HIV drugs called CCR5 receptor antagonists, ...

Recommended for you

Preventing one case of HIV saves over $225K, study shows

Feb 27, 2015

How much money would be saved if one high-risk person was prevented from contracting HIV in the United States? A new study led by a researcher at Weill Cornell Medical College and published online Feb. 24 in Medical Care, answer ...

Research captures transient details of HIV genome packaging

Feb 27, 2015

Once HIV-1 has hijacked a host cell to make copies of its own RNA genome and viral proteins, it must assemble these components into new virus particles. The orchestration of this intricate assembly process falls to a viral ...

Could an HIV drug beat strep throat, flesh-eating bacteria?

Feb 25, 2015

With antibiotic resistance on the rise, scientists are looking for innovative ways to combat bacterial infections. The pathogen that causes conditions from strep throat to flesh-eating disease is among them, but scientists ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.